StockNews.AISignal intelligence
KalVista Pharmaceuticals, Inc. · NASDAQ · Healthcare
Browse public KALV signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Chiesi Group has announced its acquisition of KalVista Pharmaceuticals for $1.9 billion in cash, equating to $14.75 per share. This deal, expected to close in Q1 2024, positions Chiesi to significantly enhance its product offerings in the pharmaceutical sector.
View signal analysisKALV's Ekterly shows strong commercial momentum and prescriber growth. Preliminary Q4 revenue reached $35 million, with $49 million for FY 2025. Prescription refills are now the main revenue driver. Ekterly is the first oral on-demand treatment for hereditary angioedema. KalVista expands Ekterly's reach into Latin America.
View signal analysisKALV to report Q1 earnings on Sept. 11 with expected losses. Projected revenue for Q1 is $2.09 million. Company's shares recently fell 2.2% to $15.61. Analysts maintain bullish ratings with price targets up to $28. Orphan designation for Sebetralstat maintained in the EU.
View signal analysisKalVista received FDA approval for a hereditary swelling disorder drug. Shares surged 33.3% in premarket trading following the news.
View signal analysisFDA extended review period for KALV's drug due to resource constraints.
View signal analysis